Infectious Diseases News and Research

RSS

Study assesses the antibody response to additional dose of COVID-19 vaccine in transplant recipients

A study has begun to assess the antibody response to an additional dose of a COVID-19 mRNA vaccine in kidney and liver transplant recipients, either alone or with a concurrent reduction in immunosuppressive medication.

31 Jan 2022

It’s Day 6 of covid, and a rapid antigen test comes back positive. stay home, say virologists.

What does it mean if a person's rapid antigen test result comes back positive after five days of isolation due to covid-19? According to the experts, that person is most likely still carrying a viral load high enough to infect others.

31 Jan 2022

Intranasal vaccine with nanoparticles offers strong protection against influenza viruses

An influenza vaccine administered through the nose and constructed with nanoparticles that enhance immune response offers strong protection against different influenza virus strains, according to researchers in the Institute for Biomedical Sciences at Georgia State University.

29 Jan 2022

Mix-and-match of COVID-19 vaccine boosters found to be safe and effective

In adults who had previously received a full regimen of a COVID-19 vaccine approved or authorized by the Food and Drug Administration (FDA), an additional dose of any of these COVID-19 vaccines was safe and prompted an immune response, according to study findings published Jan. 26 in The New England Journal of Medicine.

28 Jan 2022

New trial tests the effectiveness of hyperimmune immunoglobulin for hospitalized COVID-19 patients

This scanning electron microscope image shows SARS-CoV-2 (round gold particles) emerging from the surface of a cell cultured in the lab. SARS-CoV-2, also known as 2019-nCoV, is the virus that causes COVID-19.NIAID

28 Jan 2022

T-cell apoptosis linked to poor prognosis among COVID-19 patients

Researchers assess the probability of T-cell apoptosis in patients with severe COVID-19 who were admitted to the hospital.

26 Jan 2022

Homologous and heterologous COVID-19 booster vaccines found to be safe and immunogenic

In adults who had previously received a full regimen of any of three COVID-19 vaccines granted Emergency Use Authorization (EUA) or approved by the U.S. Food and Drug Administration, an additional booster dose of any of these vaccines was safe and prompted an immune response, according to preliminary clinical trial results reported in The New England Journal of Medicine.

26 Jan 2022

Antibodies against SARS-CoV-2 found to persist for up to 15 months after infection

In a new study, a team of researchers explored the association between total immunoglobulin (IgM, IgA, and IgG) against SARS-CoV-2 and protective immunity.

26 Jan 2022

Does remdesivir reduce mortality in moderately ill hospitalized patients with COVID-19?

A team of researchers performed a meta-analysis to investigate the use of remdesivir in the treatment of COVID-19.

26 Jan 2022

Development of synthetic molecules that can bridge T cells with SARS-CoV-2 infected cells

Scientists have recently used synthetic biology to design primary human CD8 T cells to express Spike protein-specific chimeric antigen receptors (ACE2 CAR or anti-Spike CAR).

25 Jan 2022

Current vaccines prompt the body to make effective, long-lasting T cells against SARS-CoV-2 variants

Scientists at La Jolla Institute for Immunology (LJI) have found that four COVID-19 vaccines (Pfizer-BioNTech, Moderna, J&J/Janssen, and Novavax) prompt the body to make effective, long-lasting T cells against SARS-CoV-2.

24 Jan 2022

Study could offer a novel strategy to fight respiratory syncytial virus and coronaviruses

A new approach that targets the cellular machinery that viruses need to reproduce – rather than the virus itself – appears to stem replication of a common childhood pathogen known as respiratory syncytial virus (RSV), UT Southwestern researchers report in a new study.

24 Jan 2022

Constructing SARS-CoV-2 virus-like particles in tobacco plants for vaccine development

In a study published in the latest issue of the Scientific Reports, a team of researchers constructed virus-like particles (VLPs) composed of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M), envelope (E), and nucleocapsid (N) proteins in tobacco plant using Agrobacterium-mediated delivery.

24 Jan 2022

Vaccine wars ignite in California as lawmakers seek stronger laws

California is poised to become the front line of America's vaccination wars. State lawmakers are drafting the toughest covid-19 vaccine legislation in the country, backed by a new pro-vaccine lobbying force promising to counter anti-vaccine activists who have threatened government officials and shut down public meetings across the state.

24 Jan 2022

Researchers identify a way to block Listeria infections

University of Queensland researchers have unlocked a way of fighting Listeria infections, which can cause severe illness in pregnant women and people with compromised immune systems.

23 Jan 2022

MU researchers identify highly prevalent mutations specific to Omicron variant

While the Omicron variant continues to infect people around the world, researchers at the University of Missouri have identified the highly prevalent, specific mutations that are causing the Omicron variant's high rate of infection.

22 Jan 2022

Omicron found to have higher environmental stability among SARS-CoV-2 variants

A new study compared the SARS-CoV-2 Wuhan strain and all the variants of concern (VOCs) - Alpha, Beta, Delta, and Omicron variants for their survivability and infectivity.

21 Jan 2022

New opportunity to induce remission of peanut allergy in young children through oral immunotherapy

A clinical trial funded by the National Institutes of Health has found that giving peanut oral immunotherapy to highly peanut-allergic children ages 1 to 3 years safely desensitized most of them to peanut and induced remission of peanut allergy in one-fifth. The immunotherapy consisted of a daily oral dose of peanut flour for 2.5 years.

21 Jan 2022

Nano-bubbles containing ACE2 protein can block infection from broad strains of SARS-CoV-2

Scientists at Northwestern Medicine and The University of Texas MD Anderson Cancer Center have identified natural nano-bubbles containing the ACE2 protein (evACE2) in the blood of COVID-19 patients and discovered these nano-sized particles can block infection from broad strains of SARS-CoV-2 virus in preclinical studies.

21 Jan 2022

CENTOGENE teams up with Insilico Medicine to improve therapeutic targets for Niemann-Pick disease type C

A commercial-stage company focused on generating data-driven insights to diagnose, understand and treat rare diseases, and Insilico Medicine, an end-to-end Artificial Intelligence (AI) - driven drug discovery company, today announced a research and development collaboration to accelerate the discovery of novel therapeutic targets for Niemann-Pick disease type C

21 Jan 2022

Infectious Diseases News and Research

Study assesses the antibody response to additional dose of COVID-19 vaccine in transplant recipients

It’s Day 6 of covid, and a rapid antigen test comes back positive. stay home, say virologists.

Intranasal vaccine with nanoparticles offers strong protection against influenza viruses

Mix-and-match of COVID-19 vaccine boosters found to be safe and effective

New trial tests the effectiveness of hyperimmune immunoglobulin for hospitalized COVID-19 patients

T-cell apoptosis linked to poor prognosis among COVID-19 patients

Homologous and heterologous COVID-19 booster vaccines found to be safe and immunogenic

Antibodies against SARS-CoV-2 found to persist for up to 15 months after infection

Does remdesivir reduce mortality in moderately ill hospitalized patients with COVID-19?

Development of synthetic molecules that can bridge T cells with SARS-CoV-2 infected cells

Current vaccines prompt the body to make effective, long-lasting T cells against SARS-CoV-2 variants

Study could offer a novel strategy to fight respiratory syncytial virus and coronaviruses

Constructing SARS-CoV-2 virus-like particles in tobacco plants for vaccine development

Vaccine wars ignite in California as lawmakers seek stronger laws

Researchers identify a way to block Listeria infections

MU researchers identify highly prevalent mutations specific to Omicron variant

Omicron found to have higher environmental stability among SARS-CoV-2 variants

New opportunity to induce remission of peanut allergy in young children through oral immunotherapy

Nano-bubbles containing ACE2 protein can block infection from broad strains of SARS-CoV-2

CENTOGENE teams up with Insilico Medicine to improve therapeutic targets for Niemann-Pick disease type C

NGS for Infectious Disease Surveillance eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News